The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment. Inavolisib in combination with ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

Dr Mohan engages with Nurse Goff, Dr Mann, and Nurse Brigle to explore effective multidisciplinary approaches for managing adverse events (AEs) associated with bispecific therapies and compares the AE ...

EP: 4.Handling Dose Modifications and Treatment Interruptions Due to AEs With Bispecifics ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...